- Cash, cash equivalents, and marketable securities totaled $614 million at the end of Q2 2025, down from $714 million at the end of 2024, primarily due to completion of a $200 million share repurchase program.
- Dynavax reported record Q2 2025 net product revenue for HEPLISAV-B at $92 million, a 31% increase year-over-year.
- GAAP net income was $19 million in Q2 2025 compared to $11 million in Q2 2024.
- HEPLISAV-B gross margin improved to 85% in Q2 2025 from 83% in Q2 2024, with full-year 2025 gross margin expected around 80%.
- Non-GAAP adjusted EBITDA improved to $37 million in Q2 2025 from $20 million in Q2 2024.
- R&D expenses increased slightly to $17 million in Q2 2025 from $15 million in Q2 2024, reflecting pipeline progress.
- SG&A expenses rose to $50 million in Q2 2025 from $42 million in Q2 2024, mainly due to $13 million in proxy contest-related costs.
- Total revenues for Q2 2025 were approximately $95 million, up 29% year-over-year.
Related items and other data are not available for this feed item.
Dafinchi